Paul Mieyal

Dr. Mieyal is a Managing Director with Outcome Capital’s biotechnology practice. He brings over 20 years of public and private early-stage life sciences investment and operational experience.

Prior to joining Outcome Capital, Dr. Mieyal most recently served as Managing Director of Life Sciences Investments at Wexford Capital. He was previously Vice President of Wechsler & Co., a broker-dealer and proprietary investment firm.

Dr. Mieyal has served as a director or observer on the boards of numerous life sciences companies, including AZTherapies, Danube Pharmaceuticals, Ellipse Technologies, ElMinda Ltd, GlobeImmune, Interventional Spine, Invuity (IVTY), MiCardia, Microbiogen Pty, Nephros (NEPH), Nile Therapeutics (NLTX), OncoVista (OVIT), Onset Medical, Optiscan Biomedical, Pear Tree Pharmaceuticals, Rebound Therapeutics, Reverse Medical, Shape Memory Therapeutics, Sophono, Tigris Pharmaceuticals, and Viseon.

From 2010 to 2012, Dr. Mieyal served as the CEO of publicly-traded Nephros, Inc. (NEPH), during which period, he completed strategic in-licensing and out-licensing transactions for the company’s products and led negotiations with the FDA which resulted in the clearance of the company’s hemodiafiltration system in the U.S.

Dr. Mieyal earned his Ph.D. in Pharmacology from New York Medical College and his B.A. in Chemistry and Psychology from Case Western Reserve University. He is a Chartered Financial Analyst and a member of the CFA Institute, the CFA Society of New York, and the New York Academy of Sciences. He is a FINRA Registered Securities Representative holding Series 79 and 63 registrations.